ProKidney Corp. (NASDAQ:PROK - Get Free Report) insider Control Empresarial De Capital acquired 100,000 shares of the company's stock in a transaction that occurred on Wednesday, April 16th. The stock was bought at an average cost of $0.75 per share, with a total value of $75,000.00. Following the purchase, the insider now owns 73,430,330 shares in the company, valued at $55,072,747.50. The trade was a 0.14 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.
Control Empresarial De Capital also recently made the following trade(s):
- On Monday, April 14th, Control Empresarial De Capital purchased 268,105 shares of ProKidney stock. The stock was purchased at an average price of $0.73 per share, with a total value of $195,716.65.
- On Thursday, April 10th, Control Empresarial De Capital bought 1,032,218 shares of ProKidney stock. The stock was purchased at an average cost of $0.61 per share, with a total value of $629,652.98.
ProKidney Price Performance
ProKidney stock opened at $0.79 on Friday. ProKidney Corp. has a 1 year low of $0.46 and a 1 year high of $4.44. The company has a market capitalization of $231.49 million, a P/E ratio of -1.44 and a beta of 1.52. The business has a 50 day moving average of $1.03 and a 200-day moving average of $1.51.
ProKidney (NASDAQ:PROK - Get Free Report) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.03). The firm had revenue of $0.08 million for the quarter. Equities analysts anticipate that ProKidney Corp. will post -0.57 EPS for the current year.
Hedge Funds Weigh In On ProKidney
Hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd bought a new stake in ProKidney in the third quarter valued at approximately $41,000. ProShare Advisors LLC raised its holdings in ProKidney by 57.3% during the 4th quarter. ProShare Advisors LLC now owns 30,879 shares of the company's stock worth $52,000 after purchasing an additional 11,250 shares during the last quarter. Sei Investments Co. acquired a new position in shares of ProKidney in the 4th quarter worth approximately $69,000. JPMorgan Chase & Co. boosted its stake in shares of ProKidney by 65.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 46,830 shares of the company's stock valued at $90,000 after purchasing an additional 18,472 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of ProKidney during the fourth quarter worth $88,000. 51.59% of the stock is currently owned by institutional investors.
ProKidney Company Profile
(
Get Free Report)
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
